Clobazam: A Safe, Efficacious, and Newly Rediscovered Therapeutic for Epilepsy.

Clobazam: A Safe, Efficacious, and Newly Rediscovered Therapeutic for Epilepsy. CNS Neurosci Ther. 2015 Apr 28; Authors: Gauthier AC, Mattson RH Abstract Clobazam is an oral 1,5-benzodiazepine used worldwide for the treatment of many types of epilepsies, although it is currently only approved for Lennox-Gastaut syndrome in the USA. This anticonvulsant and anxiolytic therapeutic has repeatedly demonstrated great efficacy and a high safety profile in refractory epilepsy as well as in a few monotherapy trials in both children and adults. Clobazam allosterically activates the GABAA receptor, and it binds less to subunits that mediate sedative effects than other benzodiazepines. It acts quickly, maintaining a therapeutic effect for a long duration due to its active metabolite, N-desmethylclobazam. Dosage is between 5 mg and 40 mg a day, depending on patient weight, efficacy, and tolerability. Efficacy tolerance has not been a problem in the best studies. Clobazam has provided many benefits to epileptic patients. It should be used by clinicians early as an adjuvant therapy in the treatment of refractory epilepsy and even considered as monotherapy in a broad spectrum of epilepsy syndromes. PMID: 25917225 [PubMed - as supplied by publisher]
Source: CNS Neuroscience and Therapeutics - Category: Neuroscience Authors: Tags: CNS Neurosci Ther Source Type: research

Related Links:

ConclusionHalf of the patients had not perceived clear benefit from VNS, and all but one terminated VNS without worsening of seizures within one year. The true outcome of long-term VNS is difficult to assess in real-world practice. The effect may be overestimated due to confounding factors, particularly the common introduction of novel AEDs and the natural course of the disorder. Patients without perceived benefit from long-term VNS should not routinely remain on treatment and be subject to undue generator re-implantations.
Source: Seizure - Category: Neurology Source Type: research
Publication date: Available online 20 September 2019Source: Journal of Cardiology CasesAuthor(s): Josef Finsterer
Source: Journal of Cardiology Cases - Category: Cardiology Source Type: research
In this report, we describe using zebrafish with reduced activity of Pnpo as an animal model. Knocking down zPnpo resulted in developmental anomalies including brain malformation and impaired locomotor activity, similar to the clinical features of PNPO-deficiency NEE. Other anomalies include a defective circulation system. These anomalies were significantly alleviated by co-injecting either zpnpo or hPNPO mRNAs. As expected from clinical observations in humans, supplementing with PLP improved the morphological and behavioral anomalies. PN only showed marginal positive effects, and only in a few anomalies. Remarkably, pyrid...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Condition:   Epilepsy Intervention:   Device: Vagus nerv stimulator Sponsors:   Oslo University Hospital;   Danish Epilepsy Center, Dianalund,Denmark;   Rigshospitalet, Denmark;   North German Epilepsy Center, Hamburg, Germany;   Universitaire Ziekenhuizen Leuven;   Lund University Hospital;   Sahlgrenska University Hospital, Sweden;   University Ho spital Lindkjøping, Lindkjøping, Sweden;   Tampere University Hospital Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Epilepsy Intervention:   Sponsor:   National Institute of Neurological Disorders and Stroke (NINDS) Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Epilepsy Intervention:   Device: Vagus nerv stimulator Sponsors:   Oslo University Hospital;   Danish Epilepsy Center, Dianalund,Denmark;   Rigshospitalet, Denmark;   North German Epilepsy Center, Hamburg, Germany;   Universitaire Ziekenhuizen Leuven;   Lund University Hospital;   Sahlgrenska University Hospital, Sweden;   University Ho spital Lindkjøping, Lindkjøping, Sweden;   Tampere University Hospital Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Epilepsy Intervention:   Sponsor:   National Institute of Neurological Disorders and Stroke (NINDS) Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: September 2019Source: Alzheimer's &Dementia, Volume 15, Issue 9Author(s): Alzheimer's
Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association - Category: Geriatrics Source Type: research
Publication date: Available online 17 September 2019Source: Multiple Sclerosis and Related DisordersAuthor(s): Mihaela Bustuchina VlaicuAbstractThis is a review paper, essentially a commentary with summary of literature that actualizes the problem of epilepsy in patients with multiple sclerosis. There is a bidirectional relation between multiple sclerosis and epilepsy. A possible associate pathophysiological pathway is considered. In multiple sclerosis, a combination of grey matter involvement and inflammation could influence epileptogenesis. Patients with multiple sclerosis have individual profiles and an inter-individual...
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
The families will hold up a giant invoice outside the DoH for the £231,000 they have collectively spent on the private prescriptions for their children. They'll then deliver handwritten letters to Downing Street.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
More News: Brain | Children | Epilepsy | Neurology | Neuroscience | Study